Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation

Toxicology Letters

Volumn 222, Issue 1, 2013, Pages 1-9

  Zhang, Yi ^a   Hu, Hao ^b   Song, Lu ^a   Cai, Lin ^a   Wei, Renxiong ^a   Jin, Wei ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Epirubicin; Microrna; Mirna 302b; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIRUBICIN; MICRORNA; MICRORNA 302B; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EPIRUBICIN; MICRORNA; MIRNA-302B; OSTEOSARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; EPIRUBICIN; HUMANS; MICRORNAS; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TRANSFECTION;

EID: 84881113668     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.06.242     Document Type: Article

References (48)

1. Abukhdeir A.M., Park B.H. P21 and p27: roles in carcinogenesis and drug resistance. Expert Reviews in Molecular Medicine 2008, 10:e19.
2. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 5381:1322-1326.
3. Anindo M.I., Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. International Journal of Surgery 2012, 9:443-449.
4. Anninga J.K., Gelderblom H., Fiocco M., Kroep J.R., Taminiau A.H., Hogendoorn P.C., Egeler R.M. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. European Journal of Cancer 2011, 16:2431-2445.
5. Bacci G., Longhi A., Versari M., Mercuri M., Briccoli A., Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006, 5:1154-1161.
6. Basaran M., Bavbek E.S., Saglam S., Eralp L., Sakar B., Atalar A.C., Bilgic B., Ozger H., Onat H. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology 2007, 3-4:255-260.
7. Chen P.S., Su J.L., Hung M.C. Dysregulation of microRNAs in cancer. Journal of Biomedical Science 2012, 19:90.
8. Chen J., Tian W., Cai H., He H., Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Medical Oncology 2012, 4:2527-2534.
9. Cho W.C. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opinion on Therapeutic Targets 2012, 8:747-759.
10. D'Adamo D.R. Appraising the current role of chemotherapy for the treatment of sarcoma. Seminars in Oncology 2011, 38:s19-s29.
11. Errani C., Longhi A., Rossi G., Rimondi E., Biazzo A., Toscano A., Alì N., Ruggieri P., Alberghini M., Picci P., Bacci G., Mercuri M. Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy 2011, 2:217-227.
12. Featherstone J.M., Speers A.G., Lwaleed B.A., Hayes M.C., Cooper A.J., Birch B.R. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. BJU International 2005, 7:1091-1098.
13. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA: A Cancer Journal for Clinicians 2005, 3:178-194.
14. Gougelet A., Pissaloux D., Besse A., Perez J., Duc A., Dutour A., Blay J.Y., Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International Journal of Cancer 2011, 3:680-690.
15. Harake D., Franco V.I., Henkel J.M., Miller T.L., Lipshultz S.E. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiology 2012, 4:647-670.
16. Hu H., Zhang Y., Cai X.H., Huang J.F., Cai L. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncology Letters 2012, 5:1037-1042.
17. Hu S., Wilson K.D., Ghosh Z., Han L., Wang Y., Lan F., Ransohoff K.J., Burridge P., Wu J.C. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 2013, 2:259-268.
18. Hummel R., Hussey D.J., Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. European Journal of Cancer 2010, 2:298-311.
19. Jaffe N. Osteosarcoma: review of the past, impact on the future - the American experience. Cancer Treatment and Research 2009, 152:239-262.
20. Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncology 2010, 7:670-678.
21. Jansson M.D., Lund A.H. MicroRNA and cancer. Molecular Oncology 2012, 6:590-610.
22. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncology 2012, 6:e249-e258.
23. Li D., Cui Q., Liu Y., Wang X., Liu C., Liu S., Zeng Y. Chemotherapy response analysis for osteosarcom with intra-arterial chemotherapy by subcutaneous implantable delivery system. Pathology Oncology Research 2011, 4:947-953.
24. Lipchina I., Elkabetz Y., Hafner M., Sheridan R., Mihailovic A., Tuschl T., Sander C., Studer L., Betel D. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes & Development 2011, 20:2173-2186.
25. Lin S.L., Chang D.C., Ying S.Y., Leu D., Wu D.T. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Research 2010, 22:9473-9482.
26. Liu R., Chen X., Du Y., Yao W., Shen L., Wang C., Hu Z., Zhuang R., Ning G., Zhang C., Yuan Y., Li Z., Zen K., Ba Y., Zhang C.Y. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical Chemistry 2012, 3:610-618.
27. Lu K.H., Yang H.W., Su C.W., Lue K.H., Yang S.F., Hsieh Y.S. Phyllanthus urinaria suppresses human osteosarcoma cell invasion and migration by transcriptionally inhibiting u-PA via ERK and Akt signaling pathways. Food and Chemical Toxicology 2013, 52:193-199.
28. Luzi E., Marini F., Tognarini I., Galli G., Falchetti A., Brandi M.L. The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. Nucleic Acid Therapeutics 2012, 2:103-108.
29. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer 2009, 9(March (3)):153-166.
30. Mazda M., Nishi K., Naito Y., Ui-Tei K. E-cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing. PLoS ONE 2011, 12:e28688.
31. Nikolényi A., Sükösd F., Kaizer L., Csörgo E., Vörös A., Uhercsák G., Ormándi K., Lázár G., Thurzó L., Brodowicz T., Kahán Z. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology 2011, 3-4:269-277.
32. O'Day K., Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Review of Anticancer Therapy 2009, 4:511-523.
33. Peng C., Zhang X., Yu H., Wu D., Zheng J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. International Journal of Gynecological Cancer 2011, 2:280-288.
34. Poliseno L., Salmena L., Riccardi L., Fornari A., Song M.S., Hobbs R.M., Sportoletti P., Varmeh S., Egia A., Fedele G., Rameh L., Loda M., Pandolfi P.P. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Science Signaling 2010, 117:ra29.
35. Ritter J., Bielack S.S. Osteosarcoma. Annals of Oncology 2010, 7:320-325.
36. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337.
37. Sapre N., Selth L.A. Circulating MicroRNAs as biomarkers of prostate cancer: the state of play. Prostate Cancer 2013, 2013:539680.
38. Simmons Kovacs L.A., Orlando D.A., Haase S.B. Transcription networks and cyclin/CDKs: the yin and yang of cell cycle oscillators. Cell Cycle 2008, 17:2626-2629.
39. Sukata T., Sumida K., Kushida M., Ogata K., Miyata K., Yabushita S., Uwagawa S. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicology Letters 2011, 200:46-52.
40. Sun W.L., Chen J., Wang Y.P., Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011, 9:1035-1044.
41. Swanton C., Szallasi Z., Brenton J.D., Downward J. Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Research 2008, 5:214.
42. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database of Systematic Reviews 2010, 5:CD005006.
43. Wang F., Liu M., Li X., Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Letters 2013, 5:488-495.
44. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 1:47-59.
45. Zhang B., Shi Z.L., Liu B., Yan X.B., Feng J., Tao H.M. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anti-Cancer Drugs 2010, 3:288-296.
46. Zhang J., Zhao H., Gao Y., Zhang W. Secretory miRNAs as novel cancer biomarkers. Biochimica et Biophysica Acta 2012, 1:32-43.
47. Zhang Y., Wei R.X., Zhu X.B., Cai L., Jin W., Hu H. Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anti-Cancer Drugs 2012, 2:212-219.
48. Zhang Y., Song L., Cai L., Wei R., Hu H., Jin W. Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food and Chemical Toxicology 2013, 53:325-333.